G protein-coupled receptors (GPCRs) are responsible for the majority of cellular responses to hormones and neurotransmitters as well as the senses of sight, olfaction and taste. The paradigm of GPCR signaling is the activation of a heterotrimeric GTP binding protein (G protein) by an agonist-occupied receptor. The β2 adrenergic receptor (β2AR) activation of Gs, the stimulatory G protein for adenylyl cyclase, has long been a model system for GPCR signaling. Here we present the crystal structure of the active state ternary complex composed of agonist-occupied monomeric β2AR and nucleotide-free Gs heterotrimer. The principal interactions between the β2AR and Gs involve the amino and carboxyl terminal α-helices of Gs, with conformational changes propagating to the nucleotide-binding pocket. The largest conformational changes in the β2AR include a 14 Å outward movement at the cytoplasmic end of transmembrane segment 6 (TM6) and an alpha helical extension of the cytoplasmic end of TM5. The most surprising observation is a major displacement of the alpha helical domain of Gαs relative to the ras-like GTPase domain. This crystal structure represents the first high-resolution view of transmembrane signaling by a GPCR.

Summary G protein-coupled receptors (GPCRs) represent the largest family of membrane receptors1 that instigate signaling through nucleotide exchange on heterotrimeric G proteins. Nucleotide exchange, or more precisely GDP dissociation from the G protein α-subunit, is the key step toward G protein activation and initiation of downstream signaling cascades. Despite a wealth of biochemical and biophysical studies on inactive and active conformations of several heterotrimeric G proteins, the molecular underpinnings of G protein activation remain elusive. To characterize this mechanism we applied peptide amide hydrogen-deuterium exchange mass spectrometry (DXMS) to probe changes in the structure of the heterotrimeric G protein Gs (the stimulatory G protein for adenylyl cyclase) upon formation of a complex with agonist-bound β2 adrenergic receptor (β2AR). Our studies reveal structural links between the receptor binding surface and the nucleotide-binding pocket of Gs that undergo higher levels of hydrogen-deuterium exchange (HX) than would be predicted from the crystal structure of the β2AR-Gs complex. Together with x-ray crystallographic and electron microscopic data of the β2AR-Gs complex (ref 2 and Westfield et al, manuscript submitted), we provide a rationale for a mechanism of nucleotide exchange whereby the receptor perturbs the structure of the amino-terminal region of α-subunit of Gs and consequently alters the ‘P-loop’ that binds the β-phosphate in GDP. As with the ras-family of small molecular weight G proteins, P-loop stabilization and β-phosphate coordination are key determinants of GDP (and GTP) binding affinity.

The active-state complex between an agonist-bound receptor and a guanine nucleotide-free G protein represents the fundamental signaling assembly for the majority of hormone and neurotransmitter signaling. We applied single-particle electron microscopy (EM) analysis to examine the architecture of agonist-occupied β 2 -adrenoceptor (β 2 AR) in complex with the heterotrimeric G protein Gs (Gαsβγ). EM 2D averages and 3D reconstructions of the detergent-solubilized complex reveal an overall architecture that is in very good agreement with the crystal structure of the active-state ternary complex. Strikingly however, the α-helical domain of Gαs appears highly flexible in the absence of nucleotide. In contrast, the presence of the pyrophosphate mimic foscarnet (phosphonoformate), and also the presence of GDP, favor the stabilization of the α-helical domain on the Ras-like domain of Gαs. Molecular modeling of the α-helical domain in the 3D EM maps suggests that in its stabilized form it assumes a conformation reminiscent to the one observed in the crystal structure of Gαs-GTPγS. These data argue that the α-helical domain undergoes a nucleotidedependent transition from a flexible to a conformationally stabilized state.G protein-coupled receptor | negative stain electron microscopy | random conical tilt T he majority of hormones and neurotransmitters communicate information to cells via G protein-coupled receptors (GPCRs), which instigate intracellular signaling by activating their cognate heterotrimeric G proteins on the cytoplasmic side. GPCRs constitute the largest family of membrane proteins and play essential roles in regulating every aspect of normal physiology, thereby representing major pharmacological targets. Despite a wealth of biochemical and biophysical studies on inactive and active conformations of several heterotrimeric G proteins, the molecular underpinnings of G-protein activation remain elusive. The β 2 -adrenergic receptor (β 2 AR) and its complex with heterotrimeric stimulatory G-protein Gs (Gαsβγ) represent an ideal model system for the large family of GPCRs activated by diffusible ligands. Agonist binding to the β 2 AR promotes interactions with GDP-bound Gsαβγ heterotrimer, leading to the exchange of GDP for GTP, and the functional dissociation of Gs into Gα-GTP and Gβγ subunits. To examine the architecture of agonist occupied β 2 AR in complex with Gαsβγ under different conditions, we used electron microscopy (EM) and single-particle analysis. Because of the limited size of the protein complex (∼148 kDa), we visualized specimens embedded in negative stain, which provides sufficient contrast from relatively small protein assemblies (1). This approach allowed us to obtain 2D projection averages and 3D reconstructions that provided new insights into dynamic features of the β 2 AR-Gs complex, and helped guide a successful approach to crystallize the complex enabling a high-resolution structure (2). Results and DiscussionIn a first step, we sought to examine the architecture of complexes in the nucleot...

Food restriction enhances sensitivity to the reinforcing effects of a variety of drugs of abuse including opiates, nicotine, and psychostimulants. Food restriction has also been shown to alter a variety of behavioral and pharmacological responses to dopaminergic agonists, including an increased sensitivity to the locomotor stimulatory effects of direct-and indirect-dopamine agonists, elevated extracellular dopamine levels in responses to psychostimulants, as well as suppression of agonist-induced yawning. Behavioral and molecular studies suggest that augmented dopaminergic responses observed in food-restricted animals result from a sensitization of the dopamine D2 receptor; however, little is known about how food restriction affects dopamine D3 receptor function. The current studies were aimed at better defining the effects of food restriction on D2 and D3 receptor function by assessing the capacity of 5,6, to induce yawning, penile erection (PE), hypothermia, and locomotor activity in free-fed and food-restricted rats. Food restriction resulted in a suppression of pramipexole-induced yawning, a sensitized hypothermic response, and an enhanced locomotor response to pramipexole, effects that are suggestive of an enhanced D2 receptor activity; no effect on pramipexoleinduced PE was observed. Antagonist studies further supported a food restriction-induced enhancement of the D2 receptor activity because the D2 antagonist 3-[4-(4-chlorophenyl)-4-hydroxypiperidin-l-yl]methyl-1H-indole (L741,626) recovered pramipexoleinduced yawning to free-fed levels, whereas yawning and PE were suppressed following pretreatment with the D3 antagonist N-{4- [4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine-2-yl-benzamide hydrochloride (PG01037). The results of the current studies suggest that food restriction sensitized rats to the D2-mediated effects of pramipexole while having no effect on the D3-mediated effects of pramipexole.

BackgroundSurvivin is known playing a role in drug resistance. However, its role in bortezomib-mediated inhibition of growth and induction of apoptosis is unclear. There are conflicting reports for the effect of bortezomib on survivin expression, which lacks of a plausible explanation. Methods: In this study, we tested cancer cells with both p53 wild type and mutant/null background for the relationship of bortezomib resistance with survivin expression and p53 status using MTT assay, flow cytometry, DNA fragmentation, caspase activation, western blots and RNAi technology.ResultsWe found that cancer cells with wild type p53 show a low level expression of survivin and are sensitive to treatment with bortezomib, while cancer cells with a mutant or null p53 show a high level expression of survivin and are resistant to bortezomib-mediated apoptosis induction. However, silencing of survivin expression utilizing survivin mRNA-specific siRNA/shRNA in p53 mutant or null cells sensitized cancer cells to bortezomib mediated apoptosis induction, suggesting a role for survivin in bortezomib resistance. We further noted that modulation of survivin expression by bortezomib is dependent on p53 status but independent of cancer cell types. In cancer cells with mutated p53 or p53 null, bortezomib appears to induce survivin expression, while in cancer cells with wild type p53, bortezomib downregulates or shows no significant effect on survivin expression, which is dependent on the drug concentration, cell line and exposure time.ConclusionsOur findings, for the first time, unify the current inconsistent findings for bortezomib treatment and survivin expression, and linked the effect of bortezomib on survivin expression, apoptosis induction and bortezomib resistance in the relationship with p53 status, which is independent of cancer cell types. Further mechanistic studies along with this line may impact the optimal clinical application of bortezomib in solid cancer therapeutics.